Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us ![]()
About
PEGS Boston SummitPEGS Boston Summit
Not Confirmed
Not Confirmed
11 May-15 November, 2026
DIA Global Annual Meet...DIA Global Annual Meeting
Not Confirmed
Not Confirmed
14-18 June, 2026
Discovery EuropeDiscovery Europe
Not Confirmed
Not Confirmed
15-16 June, 2026
List your booth number for exhibitions, ask us
CONTACT DETAILS





Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
PEGS Boston SummitPEGS Boston Summit
Industry Trade Show
Not Confirmed
11 May-15 November, 2026
DIA Global Annual Meet...DIA Global Annual Meeting
Industry Trade Show
Not Confirmed
14-18 June, 2026
Discovery EuropeDiscovery Europe
Industry Trade Show
Not Confirmed
15-16 June, 2026
Digital content

11 Jun 2026
// BUSINESSWIRE
https://www.businesswire.com/news/home/20260611847737/en/Travere-Therapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4

04 Jun 2026
// BUSINESSWIRE
https://www.businesswire.com/news/home/20260604838591/en/Travere-Therapeutics-Presents-Long-Term-Open-Label-Extension-Data-from-the-Phase-3-DUPLEX-Study-at-the-63rd-European-Renal-Association-ERA-2026-Congress

02 Jun 2026
// FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/travere-bolsters-rare-kidney-disease-platform-103b-biobucks-deal-everest-btk-inhibitor

27 May 2026
// BUSINESSWIRE
https://www.businesswire.com/news/home/20260527462059/en/Travere-Therapeutics-Receives-Notice-of-Allowance-from-the-U.S.-Patent-and-Trademark-Office-for-U.S.-Patent-Application-Directed-to-Certain-Methods-of-Using-FILSPARI-sparsentan-in-IgA-Nephropathy

12 May 2026
// BUSINESSWIRE
https://www.businesswire.com/news/home/20260512102473/en/Travere-Therapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4

07 May 2026
// BUSINESSWIRE
https://www.businesswire.com/news/home/20260507216351/en/Travere-Therapeutics-to-Participate-at-Upcoming-Investor-Conferences
ABOUT THIS PAGE